Compare NextEra Energy, Inc. (NEE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Sana Biotechnology Inc — how do they compare? NextEra Energy, Inc. trades at $77.4 (market cap $161.39B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: NextEra Energy, Inc. is far larger — about 192.9× Sana Biotechnology Inc's market cap, and NextEra Energy, Inc. pays a 3.22% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and Sana Biotechnology Inc for 23 Days on average.
| NEE | SANA | |
|---|---|---|
Market Cap | $161.39B | $836.71M |
Volume | 11,780,955 | 4,507,444 |
Sector | Utilities | Health |
52-Week High | $97.88 | $5.92 |
52-Week Low | $75.49 | $2.68 |
Typical Hold Time | 83 Days | 23 Days |
Enterprise Value | $268.72B | $749.96M |
Dividend Yield | 3.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $77.38, up 0.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed recent earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, with strong profitability margins including a 32.4% net income margin. Recent news highlights strategic growth initiatives, such as the $22.3 billion Project Star energy infrastructure partnership announced on September 30, 2026.
The outlook is supported by analyst consensus with a $96 price target and 66.7% buy ratings, but risks include rising debt levels and competitive pressures. The stock offers potential upside from execution on growth projects, though investors face headwinds from interest rate sensitivity and execution risks in large-scale developments.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
